Across TCGA pan-cancer cohorts, SLC50A1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC50A1 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SLC50A1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC50A1 expression acts as an unfavorable survival marker.
STAD, COAD, and ESCA are the cancer types where SLC50A1 Mutation most reproducibly stratifies survival.